Novavax starts early stage Ebola vaccine trial
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 12:18PM CST
JNJ: 99.62 (+1.18), NVAX: 8.80 (+0.40), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
Johnson & Johnson announces Ebola vaccine development consortia
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 7:54AM CST
JNJ: 99.62 (+1.18), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
J&J begins Ebola vaccine trial in U.K.
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 3:07AM CST
JNJ: 99.62 (+1.18)
Ebola: Search For A Vaccine On The Fast Track
Tony Daltorio - at Seeking Alpha - Mon Oct 27, 11:39AM CDT
JNJ: 99.62 (+1.18), NLNK: 38.84 (+1.51), GSK: 47.94 (+1.99)
Wall Street Breakfast: Bank Of England Keeps Rates Low
Wall Street Breakfast - Seeking Alpha - Wed Oct 22, 5:32AM CDT
Economy The majority of the Bank of England's Monetary Policy Committee remains against raising interest rates, voting 7-2 to maintain a record low rate of 0.5%, minutes from the October 7-8 meeting show. The minutes said that for most members,...
TSLA: 203.77 (+0.89), F: 16.30 (-0.06), SNE: 27.30 (+0.19), TM: 132.49 (+0.67), WBS: 34.26 (+0.22), JNJ: 99.62 (+1.18), GTAT: 0.44 (+0.03), SPY: 209.78 (+0.86), IBM: 160.40 (+1.88), EMC: 27.99 (+0.12), AYR: 21.42 (+0.11), HMC: 32.87 (+0.14), AAPL: 127.08 (+0.62), CSCO: 29.43 (-0.03), BOND: 109.14 (-0.10), FCAU: 14.53 (+0.06), QQQ: 106.91 (+0.91), TOT: 54.14 (-0.36), ARTX: 2.44 (+0.06), GM: 37.62 (-0.40)
Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
GlobeNewswire - Wed Oct 22, 1:06AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today a global license and supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
JNJ: 99.62 (+1.18)
Bavarian Nordic Receives Order From the Canadian Government to Supply IMVAMUNE(R) Smallpox Vaccine
GlobeNewswire - Tue Aug 26, 1:08AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that it has signed two contracts with the Canadian authorities for the delivery of a total of 65,700 doses of IMVAMUNE smallpox vaccine. The vaccines will be delivered in 2014 and 2015. This will bring the current number of delivered doses of IMVAMUNE to Canada above 100,000 doses.
Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer
GlobeNewswire - Thu Jul 24, 12:57AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been treated in an NCI-sponsored Phase 1 study of MVA-BN Brachyury in patients with advanced cancer.